Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Neoplasms
Interventions: DRUG: alpelisib|DRUG: placebo|DRUG: nab-paclitaxel
Sponsor: Novartis Pharmaceuticals